In case of an overdose of flotufolastat F-18, maintain patients hydrated and promote frequent voiding to reduce the effects of radiation exposure. Diuretics can also be used in case of overdose. The product label also recommends estimating the radiation-effective dose administered to the patient, if possible.L46731 The carcinogenic or mutagenic potential of flotufolastat F-18 in animals has not been evaluated. However, this compound can potentially be mutagenic due to the F-18 radionuclide. Animal studies evaluating the potential impairment of fertility have not been conducted.L46731
Flotufolastat F-18 (18F-rhPSMA-7.3) is an 18F-labeled ligand that targets the prostate-specific membrane antigen (PSMA).A259846,L46731 In patients with recurrent prostate cancer that require localized treatment, the use of 18F-labeled ligands for positron emission tomography (PET) offers accurate diagnostic imaging. Unlike 68Ga-labeled PSMA-targeting ligands, 18F-labeled compounds targeting this protein have a longer half-life and can be produced in larger batches. Flotufolastat F-18 is a diastereoisomer of 18F-rhPSMA-7, and compared to the other diastereoisomers of this compound, flotufolastat F-18 has a faster clearance from blood pool, liver, and kidney, and a high level of accumulation in tumors.A259846
In May 2023, the FDA approved the use of flotufolastat F-18 for PET of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.L46731,L46737 This is the first FDA-approved, PSMA-targeted imaging agent developed with proprietary radiohybrid (rh) technology.L46737 Additional studies have shown that in patients with primary prostate cancer, the use of flotufolastat F-18 shows led to low interreader variation and a good distinction between primary-tumor activity and bladder background activity.A259851
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Flutamide | Flutamide may decrease effectiveness of Flotufolastat F-18 as a diagnostic agent. |
| Nilutamide | Nilutamide may decrease effectiveness of Flotufolastat F-18 as a diagnostic agent. |
| Bicalutamide | Bicalutamide may decrease effectiveness of Flotufolastat F-18 as a diagnostic agent. |
| Cyproterone acetate | Cyproterone acetate may decrease effectiveness of Flotufolastat F-18 as a diagnostic agent. |
| Enzalutamide | Enzalutamide may decrease effectiveness of Flotufolastat F-18 as a diagnostic agent. |
| Relugolix | Relugolix may decrease effectiveness of Flotufolastat F-18 as a diagnostic agent. |
| Apalutamide | Apalutamide may decrease effectiveness of Flotufolastat F-18 as a diagnostic agent. |
| Clascoterone | Clascoterone may decrease effectiveness of Flotufolastat F-18 as a diagnostic agent. |
| Darolutamide | Darolutamide may decrease effectiveness of Flotufolastat F-18 as a diagnostic agent. |
| Chlormadinone | Chlormadinone may decrease effectiveness of Flotufolastat F-18 as a diagnostic agent. |
| Chlormadinone acetate | Chlormadinone acetate may decrease effectiveness of Flotufolastat F-18 as a diagnostic agent. |